Cargando…

Hepatic fat is a stronger correlate of key clinical and molecular abnormalities than visceral and abdominal subcutaneous fat in youth

INTRODUCTION: Body fat distribution is strongly associated with cardiometabolic disease (CMD), but the relative importance of hepatic fat as an underlying driver remains unclear. Here, we applied a systems biology approach to compare the clinical and molecular subnetworks that correlate with hepatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Cioffi, Catherine E, Narayan, K M Venkat, Liu, Ken, Uppal, Karan, Jones, Dean P, Tran, ViLinh, Yu, Tianwei, Alvarez, Jessica A, Bellissimo, Moriah P, Maner-Smith, Kristal M, Pierpoint, Bridget, Caprio, Sonia, Santoro, Nicola, Vos, Miriam B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380953/
https://www.ncbi.nlm.nih.gov/pubmed/32699106
http://dx.doi.org/10.1136/bmjdrc-2019-001126
_version_ 1783562944906264576
author Cioffi, Catherine E
Narayan, K M Venkat
Liu, Ken
Uppal, Karan
Jones, Dean P
Tran, ViLinh
Yu, Tianwei
Alvarez, Jessica A
Bellissimo, Moriah P
Maner-Smith, Kristal M
Pierpoint, Bridget
Caprio, Sonia
Santoro, Nicola
Vos, Miriam B
author_facet Cioffi, Catherine E
Narayan, K M Venkat
Liu, Ken
Uppal, Karan
Jones, Dean P
Tran, ViLinh
Yu, Tianwei
Alvarez, Jessica A
Bellissimo, Moriah P
Maner-Smith, Kristal M
Pierpoint, Bridget
Caprio, Sonia
Santoro, Nicola
Vos, Miriam B
author_sort Cioffi, Catherine E
collection PubMed
description INTRODUCTION: Body fat distribution is strongly associated with cardiometabolic disease (CMD), but the relative importance of hepatic fat as an underlying driver remains unclear. Here, we applied a systems biology approach to compare the clinical and molecular subnetworks that correlate with hepatic fat, visceral fat, and abdominal subcutaneous fat distribution. RESEARCH DESIGN AND METHODS: This was a cross-sectional sub-study of 283 children/adolescents (7–19 years) from the Yale Pediatric NAFLD Cohort. Untargeted, high-resolution metabolomics (HRM) was performed on plasma and combined with existing clinical variables including hepatic and abdominal fat measured by MRI. Integrative network analysis was coupled with pathway enrichment analysis and multivariable linear regression (MLR) to examine which metabolites and clinical variables associated with each fat depot. RESULTS: The data divided into four communities of correlated variables (|r|>0.15, p<0.05) after integrative network analysis. In the largest community, hepatic fat was associated with eight clinical biomarkers, including measures of insulin resistance and dyslipidemia, and 878 metabolite features that were enriched predominantly in amino acid (AA) and lipid pathways in pathway enrichment analysis (p<0.05). Key metabolites associated with hepatic fat included branched-chain AAs (valine and isoleucine/leucine), aromatic AAs (tyrosine and tryptophan), serine, glycine, alanine, and pyruvate, as well as several acylcarnitines and glycerophospholipids (all q<0.05 in MLR adjusted for covariates). The other communities detected in integrative network analysis consisted of abdominal visceral, superficial subcutaneous, and deep subcutaneous fats, but no clinical variables, fewer metabolite features (280, 312, and 74, respectively), and limited findings in pathway analysis. CONCLUSIONS: These data-driven findings show a stronger association of hepatic fat with key CMD risk factors compared with abdominal fats. The molecular network identified using HRM that associated with hepatic fat provides insight into potential mechanisms underlying the hepatic fat–insulin resistance interface in youth.
format Online
Article
Text
id pubmed-7380953
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-73809532020-08-04 Hepatic fat is a stronger correlate of key clinical and molecular abnormalities than visceral and abdominal subcutaneous fat in youth Cioffi, Catherine E Narayan, K M Venkat Liu, Ken Uppal, Karan Jones, Dean P Tran, ViLinh Yu, Tianwei Alvarez, Jessica A Bellissimo, Moriah P Maner-Smith, Kristal M Pierpoint, Bridget Caprio, Sonia Santoro, Nicola Vos, Miriam B BMJ Open Diabetes Res Care Genetics/Genomes/Proteomics/Metabolomics INTRODUCTION: Body fat distribution is strongly associated with cardiometabolic disease (CMD), but the relative importance of hepatic fat as an underlying driver remains unclear. Here, we applied a systems biology approach to compare the clinical and molecular subnetworks that correlate with hepatic fat, visceral fat, and abdominal subcutaneous fat distribution. RESEARCH DESIGN AND METHODS: This was a cross-sectional sub-study of 283 children/adolescents (7–19 years) from the Yale Pediatric NAFLD Cohort. Untargeted, high-resolution metabolomics (HRM) was performed on plasma and combined with existing clinical variables including hepatic and abdominal fat measured by MRI. Integrative network analysis was coupled with pathway enrichment analysis and multivariable linear regression (MLR) to examine which metabolites and clinical variables associated with each fat depot. RESULTS: The data divided into four communities of correlated variables (|r|>0.15, p<0.05) after integrative network analysis. In the largest community, hepatic fat was associated with eight clinical biomarkers, including measures of insulin resistance and dyslipidemia, and 878 metabolite features that were enriched predominantly in amino acid (AA) and lipid pathways in pathway enrichment analysis (p<0.05). Key metabolites associated with hepatic fat included branched-chain AAs (valine and isoleucine/leucine), aromatic AAs (tyrosine and tryptophan), serine, glycine, alanine, and pyruvate, as well as several acylcarnitines and glycerophospholipids (all q<0.05 in MLR adjusted for covariates). The other communities detected in integrative network analysis consisted of abdominal visceral, superficial subcutaneous, and deep subcutaneous fats, but no clinical variables, fewer metabolite features (280, 312, and 74, respectively), and limited findings in pathway analysis. CONCLUSIONS: These data-driven findings show a stronger association of hepatic fat with key CMD risk factors compared with abdominal fats. The molecular network identified using HRM that associated with hepatic fat provides insight into potential mechanisms underlying the hepatic fat–insulin resistance interface in youth. BMJ Publishing Group 2020-07-22 /pmc/articles/PMC7380953/ /pubmed/32699106 http://dx.doi.org/10.1136/bmjdrc-2019-001126 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Genetics/Genomes/Proteomics/Metabolomics
Cioffi, Catherine E
Narayan, K M Venkat
Liu, Ken
Uppal, Karan
Jones, Dean P
Tran, ViLinh
Yu, Tianwei
Alvarez, Jessica A
Bellissimo, Moriah P
Maner-Smith, Kristal M
Pierpoint, Bridget
Caprio, Sonia
Santoro, Nicola
Vos, Miriam B
Hepatic fat is a stronger correlate of key clinical and molecular abnormalities than visceral and abdominal subcutaneous fat in youth
title Hepatic fat is a stronger correlate of key clinical and molecular abnormalities than visceral and abdominal subcutaneous fat in youth
title_full Hepatic fat is a stronger correlate of key clinical and molecular abnormalities than visceral and abdominal subcutaneous fat in youth
title_fullStr Hepatic fat is a stronger correlate of key clinical and molecular abnormalities than visceral and abdominal subcutaneous fat in youth
title_full_unstemmed Hepatic fat is a stronger correlate of key clinical and molecular abnormalities than visceral and abdominal subcutaneous fat in youth
title_short Hepatic fat is a stronger correlate of key clinical and molecular abnormalities than visceral and abdominal subcutaneous fat in youth
title_sort hepatic fat is a stronger correlate of key clinical and molecular abnormalities than visceral and abdominal subcutaneous fat in youth
topic Genetics/Genomes/Proteomics/Metabolomics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380953/
https://www.ncbi.nlm.nih.gov/pubmed/32699106
http://dx.doi.org/10.1136/bmjdrc-2019-001126
work_keys_str_mv AT ciofficatherinee hepaticfatisastrongercorrelateofkeyclinicalandmolecularabnormalitiesthanvisceralandabdominalsubcutaneousfatinyouth
AT narayankmvenkat hepaticfatisastrongercorrelateofkeyclinicalandmolecularabnormalitiesthanvisceralandabdominalsubcutaneousfatinyouth
AT liuken hepaticfatisastrongercorrelateofkeyclinicalandmolecularabnormalitiesthanvisceralandabdominalsubcutaneousfatinyouth
AT uppalkaran hepaticfatisastrongercorrelateofkeyclinicalandmolecularabnormalitiesthanvisceralandabdominalsubcutaneousfatinyouth
AT jonesdeanp hepaticfatisastrongercorrelateofkeyclinicalandmolecularabnormalitiesthanvisceralandabdominalsubcutaneousfatinyouth
AT tranvilinh hepaticfatisastrongercorrelateofkeyclinicalandmolecularabnormalitiesthanvisceralandabdominalsubcutaneousfatinyouth
AT yutianwei hepaticfatisastrongercorrelateofkeyclinicalandmolecularabnormalitiesthanvisceralandabdominalsubcutaneousfatinyouth
AT alvarezjessicaa hepaticfatisastrongercorrelateofkeyclinicalandmolecularabnormalitiesthanvisceralandabdominalsubcutaneousfatinyouth
AT bellissimomoriahp hepaticfatisastrongercorrelateofkeyclinicalandmolecularabnormalitiesthanvisceralandabdominalsubcutaneousfatinyouth
AT manersmithkristalm hepaticfatisastrongercorrelateofkeyclinicalandmolecularabnormalitiesthanvisceralandabdominalsubcutaneousfatinyouth
AT pierpointbridget hepaticfatisastrongercorrelateofkeyclinicalandmolecularabnormalitiesthanvisceralandabdominalsubcutaneousfatinyouth
AT capriosonia hepaticfatisastrongercorrelateofkeyclinicalandmolecularabnormalitiesthanvisceralandabdominalsubcutaneousfatinyouth
AT santoronicola hepaticfatisastrongercorrelateofkeyclinicalandmolecularabnormalitiesthanvisceralandabdominalsubcutaneousfatinyouth
AT vosmiriamb hepaticfatisastrongercorrelateofkeyclinicalandmolecularabnormalitiesthanvisceralandabdominalsubcutaneousfatinyouth